Search results for "harm"

showing 10 items of 13866 documents

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2…

2016

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineantibodiestumor microenvironmentImmunology and AllergyMedicinetumor vaccinationPersonalized therapypersonalized therapyPharmacologyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologycheckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

2015

The 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) brought together more than 800 scientists in Mainz, Germany, from May 11–13, 2015, to present and discuss current research...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicinemedicineImmunology and Allergytumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy

2017

The 15th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) took place May 10–11, 2017, Mainz, Germany during which scientists and CIMT members from all over the world not only celeb...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyPhysiologyMeeting Reportcombination therapyCell therapy03 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicinemedicineImmunology and Allergyantibodiestumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapycancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biology030220 oncology & carcinogenesischeckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives

2021

Immuno-oncology (IO) focuses on the ability of the immune system to detect and eliminate cancer cells. Since the approval of the first immune checkpoint inhibitor, immunotherapies have become a major player in oncology treatment and, in 2021, represented the highest number of approved drugs in the field. In spite of this, there is still a fraction of patients that do not respond to these therapies and develop resistance mechanisms. In this sense, mathematical models offer an opportunity to identify predictive biomarkers, optimal dosing schedules and rational combinations to maximize clinical response. This work aims to outline the main therapeutic targets in IO and to provide a description …

0301 basic medicineOncologymedicine.medical_specialtyComputer scienceImmune checkpoint inhibitorsPharmaceutical ScienceCancer immunityReview03 medical and health sciences0302 clinical medicinePharmacy and materia medicaDosing schedulesInternal medicinemedicineTumor growthimmuno-oncologyPK/PD modelsPredictive biomarkertop-down approachMathematical modelPK/PDmathematical modelingRS1-441030104 developmental biologybottom-up approach030220 oncology & carcinogenesisSpitemiddle-out approachPharmaceutics
researchProduct

Imaging biomarkers of behavioral impairments: A pilot micro-positron emission tomographic study in a rat electrical post-status epilepticus model.

2018

Objective In patients with epilepsy, psychiatric comorbidities can significantly affect the disease course and quality of life. Detecting and recognizing these comorbidities is central in determining an optimal treatment plan. One promising tool in detecting biomarkers for psychiatric comorbidities in epilepsy is positron emission tomography (PET). Methods Results Behavioral and biochemical variables were cross-correlated with the results from two mu PET scans using the tracers [F-18]fluoro-2-deoxy-D-glucose ([F-18]FDG) and 2 '-methoxyphenyl-(N-2 '-pyridinyl)-p-F-18-fluoro-benzamidoethylpiperazine ([F-18]MPPF) to explore potential biomarkers for neurobehavioral comorbidities in an electrica…

0301 basic medicineOncologymedicine.medical_specialtyImaging biomarkerStatus epilepticusHippocampal formationAnxietyHippocampusPositron emission tomographicNesting BehaviorRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compoundEpilepsySeverity assessment0302 clinical medicineStatus EpilepticusFluorodeoxyglucose F18Internal medicinepsychiatric comorbiditieMedicineAnimalsSocial BehaviorElectroshockmedicine.diagnostic_testbusiness.industryanimal modelmedicine.diseaseElectrodes ImplantedRats030104 developmental biologyNeurologychemistryPositron emission tomographyPositron-Emission TomographyepilepsyFemale[18F]MPPFNeurology (clinical)[18F]FDGMPPFmedicine.symptomRadiopharmaceuticalsbusiness030217 neurology & neurosurgeryBiomarkersEpilepsia
researchProduct

NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocent…

2020

Introduction Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients’ quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK1-RA and palonosetron, a 5HT3-RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist. Methods Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastati…

0301 basic medicineOncologymedicine.medical_specialtyNauseamedicine.drug_classmedicine.medical_treatmentOndansetron03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineAntiemeticPharmacology (medical)carboplatin Chemotherapy-induced nausea and vomiting gemcitabine netupitant NSCLC ondansetron ovarian cancer palonosetron urothelial cancer dexamethasoneChemotherapybusiness.industryGemcitabineCarboplatin030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisVomitingmedicine.symptombusinessmedicine.drugChemotherapy-induced nausea and vomiting
researchProduct

Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes

2021

There is a growing need for biomarkers to predict therapeutic outcome in Crohn's disease (CD).The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics.Patients with CD who started biologics were enrolled. Multivariate analysis was used to evaluate whether NLR, PLR, ELR and ENLR at baseline and at w12 could predict ER (Simple Endoscopic Score for Crohn's disease [SES-CD] ≤2 or SES-CD≤2 and Rutgeerts i0-i1) after 52 weeks of treatment. Area under the curve (AUC) was calcul…

0301 basic medicineOncologymedicine.medical_specialtyNeutrophilsClinical BiochemistryDisease03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicineDrug DiscoverymedicineHumansLymphocytesRetrospective StudiesPharmacologyBiological ProductsCrohn's diseasebusiness.industryfungiOutcome measuresPrognosismedicine.diseaseInflammatory biomarkers030104 developmental biology030220 oncology & carcinogenesisMucosal healingbusinessBiomarkersExpert Opinion on Biological Therapy
researchProduct

An update on intracerebral stem cell grafts.

2018

Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for c…

0301 basic medicineOncologymedicine.medical_specialtyParkinson's diseaseTraumatic brain injurymedicine.medical_treatmentmulti-system atrophyNeuroprotection03 medical and health sciencesGraft vs Host Reaction0302 clinical medicineHuntington's diseaseCentral Nervous System DiseasesRisk FactorsInternal medicineMedicineAnimalsHumansPharmacology (medical)amyotrophic lateral sclerosiAmyotrophic lateral sclerosisStem cellbusiness.industryGeneral NeuroscienceMultiple sclerosistraumatic brain injuryStem-cell therapymedicine.diseasestroke030104 developmental biologyBlood-Brain Barriermultiple sclerosiParkinson’s diseaseneuroprotectionNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryHuntington’s diseaseStem Cell TransplantationExpert review of neurotherapeutics
researchProduct

Genomic landscape analyses in cervical carcinoma and consequences for treatment.

2020

Where we are on the road to ‘tailor-made’ precision medicine for drug-resistant cervical carcinoma? We explored studies about analyses of viral and human genomes, epigenomes and transcriptomes, DNA mutation analyses, their importance in detecting HPV sequences, mechanisms of drug resistance to established and targeted therapies with small molecule or therapeutic antibodies, to radiosensitivity and to chemoradiotherapy. The value of repurposing of old drugs initially approved for other disease indications and now considered for cervix cancer therapy is also discussed. The microbiome influences drug response and survival too. HPV genomic integration sites were less significant. Nomograms (Lee…

0301 basic medicineOncologymedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseDrug resistance030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansMicrobiomeCervixPapillomaviridaeRepurposingPharmacologybusiness.industryDNAGenomicsPrecision medicinePrognosis030104 developmental biologymedicine.anatomical_structureHuman genomeFemalebusinessChemoradiotherapyCurrent opinion in pharmacology
researchProduct

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

2017

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinePharmaceutical AdjuvantsBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicinebusinessAdjuvantmedicine.drugEarly breast cancerAnnals of Oncology
researchProduct